OXURION NV

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Oxurion (Euronext Bxls: OXUR) is developing next generation therapies for retinal vascular disease, including diabetic eye disease, the leading cause of blindness in people of working age worldwide.
Oxurion’s clinical pipeline comprises:
• THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy.
THR-149 has shown positive topline Ph 1 results for the treatment of DME. Oxurion is currently preparing a Ph 2 clinical program, expected to start in H2 20. THR-149 was developed in conjunction with Bicycle Therapeutics plc (BCYC).
• THR-687, a pan-RGD integrin antagonist, developed as a potential new standard of care for all DME patients. Positive topline results in a Ph 1 clinical study assessing it as a treatment for DME were announced in Jan 20. THR-687 is expected to enter a Ph 2 clinical trial in H1 21. THR-687 is in-licensed from Galapagos NV (GLPG).
Ticker:
OXUR
Exchange:
Euronext
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Belgium
Year Founded:
1999
Main Therapeutic Focus:
Lead Product in Development:
THR-149 and THR-687
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
OXURION NV